| Title |
Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States
|
|---|---|
| Published in |
Advances in Therapy, February 2018
|
| DOI | 10.1007/s12325-018-0667-3 |
| Pubmed ID | |
| Authors |
Ahmed M. Soliman, Eric Surrey, Machaon Bonafede, James K. Nelson, Jane Castelli-Haley |
| Abstract |
The prevalence of endometriosis and the need for treatment in the USA has led to the need to explore the contemporary cost burden associated with the disease. This retrospective cohort study compared direct and indirect healthcare costs in patients with endometriosis to a control group without endometriosis. Women aged 18-49 years with endometriosis (date of initial diagnosis = index date) were identified in the Truven Health MarketScan®Commercial database between 2010 and 2014 and female control patients without endometriosis were matched by age and index year. The following outcomes were compared: healthcare resource utilization (HRU) during the 12-month pre- and post-index periods (including inpatient admissions, pharmacy claims, emergency room visits, physician office visits, and obstetrics/gynecology visits), annual direct (medical and pharmacy) and indirect (absenteeism, short-term disability, and long-term disability) healthcare costs during the 12-month post-index period (in 2014 US$). Multivariate analyses were conducted to estimate annual total direct and indirect costs, controlling for demographics, pre-index clinical characteristics, and pre-index healthcare costs. Overall, 113,506 endometriosis patients and 927,599 controls were included. Endometriosis patients had significantly higher HRU during both the pre- and post-index periods compared to controls (p < 0.0001, all categories of HRU). Approximately two-thirds of endometriosis patients underwent an endometriosis-related surgical procedure (including laparotomy, laparoscopy, hysterectomy, oophorectomy, and other excision/ablation procedures) in the first 12 months post-index. Mean annual total adjusted direct costs per endometriosis patient during the 12-month post-index period was over three times higher than that for a non-endometriosis control [$16,573 (standard deviation (SD) = $21,336) vs. $4733 (SD = $14,833); p < 0.005]. On average, incremental direct and indirect 12-month costs per endometriosis patient were $10,002 and $2132 compared to their matched controls (p < 0.005). Endometriosis patients incurred significantly higher direct and indirect healthcare costs than non-endometriosis patients. AbbVie Inc. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 46% |
| France | 1 | 8% |
| Ireland | 1 | 8% |
| Unknown | 5 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 85% |
| Science communicators (journalists, bloggers, editors) | 2 | 15% |
Mendeley readers
The data shown below were compiled from readership statistics for 215 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 215 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 24 | 11% |
| Researcher | 23 | 11% |
| Student > Bachelor | 23 | 11% |
| Student > Ph. D. Student | 22 | 10% |
| Other | 16 | 7% |
| Other | 31 | 14% |
| Unknown | 76 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 57 | 27% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 6% |
| Nursing and Health Professions | 12 | 6% |
| Biochemistry, Genetics and Molecular Biology | 10 | 5% |
| Social Sciences | 10 | 5% |
| Other | 28 | 13% |
| Unknown | 85 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 60. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2023.
All research outputs
#670,050
of 24,466,750 outputs
Outputs from Advances in Therapy
#62
of 2,523 outputs
Outputs of similar age
#18,395
of 483,032 outputs
Outputs of similar age from Advances in Therapy
#2
of 29 outputs
Altmetric has tracked 24,466,750 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,523 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 483,032 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.